Notably, the specificity of high c-Myc-immunopositivity combined with high-risk cytogenetics reached 95.92%, suggesting that c-Myc could facilitate cytogenetics to identify AML patients who will respond to “7 + 3” induction chemotherapy more precisely than cytogenetics alone (Table 4). The gene discussed is MYC; the disease is acute myeloid leukemia.